MedTrace Logo

PPAR-gamma: a Novel Therapeutic Target for Asthma?

NCT01134835 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2015-12-03

No results posted yet for this study

Summary

To test the hypothesis that stimulation of PPAR-γ receptors has a therapeutic role in the treatment of asthma.

Conditions

Interventions

OTHER

placebo

placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks

DRUG

IMP Pioglitozone

Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.

Sponsors & Collaborators

  • University of Nottingham

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-02-29
Completion
2012-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01134835 on ClinicalTrials.gov